1. 343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). (September 2015) Authors: Michalarea, V.; Lopez, J.; Lorente, D.; Carreira, S.; Hassam, H.; Parmar, M.; Turner, A.; Hall, E.; Fandos, S. Serrano; Decordova, S.; Swales, K.; Ruddle, R.; Raynaud, F.; Tunariu, N.; Stephens, C.M.; Molife, L.R.; Banerji, U.; Plummer, R.; Bono, J. De; Yap, T.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗